Next Article in Journal
Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction
Next Article in Special Issue
Bioactivity of Eugenol: A Potential Antibiotic Adjuvant with Minimal Ecotoxicological Impact
Previous Article in Journal
Disease-Causing TIMP3 Variants and Deep Phenotyping of Two Czech Families with Sorsby Fundus Dystrophy Associated with Novel p.(Tyr152Cys) Mutation
Previous Article in Special Issue
Tannic Acid Mitigates Rotenone-Induced Dopaminergic Neurodegeneration by Inhibiting Inflammation, Oxidative Stress, Apoptosis, and Glutamate Toxicity in Rats
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 7
10.3390/ijms25073746
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?

by
Kamila Kasprzak-Drozd
1,
Przemysław Niziński
2,
Paulina Kasprzak
3,
Adrianna Kondracka
4,
Tomasz Oniszczuk
5,
Agata Rusinek
1 and
Anna Oniszczuk
1,*
1
Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland
2
Department of Pharmacology, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland
3
Department of Conservative Dentistry with Endodontics, Medical University of Lublin, Chodźki 6, 20-093 Lublin, Poland
4
Department of Obstetrics and Pathology of Pregnancy, Medical University of Lublin, Staszica 16, 20-081 Lublin, Poland
5
Department of Thermal Technology and Food Process Engineering, University of Life Sciences in Lublin, Głęboka 31, 20-612 Lublin, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(7), 3746; https://doi.org/10.3390/ijms25073746
Submission received: 20 February 2024 / Revised: 22 March 2024 / Accepted: 23 March 2024 / Published: 27 March 2024
(This article belongs to the Special Issue Bioactive Molecules of Natural Origin: Mechanisms of Action Related to Health Risks and Benefits—3rd Edition)
Browse Figures
Review Reports Versions Notes

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is influenced by a variety of factors, including environmental and genetic factors. The most significant outcome is the alteration of free fatty acid and triglyceride metabolism. Lipotoxicity, impaired autophagy, chronic inflammation, and oxidative stress, as well as coexisting insulin resistance, obesity, and changes in the composition of gut microbiota, are also considered crucial factors in the pathogenesis of MASLD. Resveratrol is a polyphenolic compound that belongs to the stilbene subgroup. This review summarises the available information on the therapeutic effects of resveratrol against MASLD. Resveratrol has demonstrated promising antisteatotic, antioxidant, and anti-inflammatory activities in liver cells in in vitro and animal studies. Resveratrol has been associated with inhibiting the NF-κB pathway, activating the SIRT-1 and AMPK pathways, normalizing the intestinal microbiome, and alleviating intestinal inflammation. However, clinical studies have yielded inconclusive results regarding the efficacy of resveratrol in alleviating hepatic steatosis or reducing any of the parameters found in MASLD in human patients. The lack of homogeneity between studies, low bioavailability of resveratrol, and population variability when compared to animal models could be the reasons for this.
Keywords: resveratrol; MASLD; polyphenols; nutraceuticals; metabolic syndrome; functional food; lipids; oxidative stress; antioxidants resveratrol; MASLD; polyphenols; nutraceuticals; metabolic syndrome; functional food; lipids; oxidative stress; antioxidants

Share and Cite

MDPI and ACS Style

Kasprzak-Drozd, K.; Niziński, P.; Kasprzak, P.; Kondracka, A.; Oniszczuk, T.; Rusinek, A.; Oniszczuk, A. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)? Int. J. Mol. Sci. 2024, 25, 3746. https://doi.org/10.3390/ijms25073746

AMA Style

Kasprzak-Drozd K, Niziński P, Kasprzak P, Kondracka A, Oniszczuk T, Rusinek A, Oniszczuk A. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)? International Journal of Molecular Sciences. 2024; 25(7):3746. https://doi.org/10.3390/ijms25073746

Chicago/Turabian Style

Kasprzak-Drozd, Kamila, Przemysław Niziński, Paulina Kasprzak, Adrianna Kondracka, Tomasz Oniszczuk, Agata Rusinek, and Anna Oniszczuk. 2024. "Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?" International Journal of Molecular Sciences 25, no. 7: 3746. https://doi.org/10.3390/ijms25073746

APA Style

Kasprzak-Drozd, K., Niziński, P., Kasprzak, P., Kondracka, A., Oniszczuk, T., Rusinek, A., & Oniszczuk, A. (2024). Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)? International Journal of Molecular Sciences, 25(7), 3746. https://doi.org/10.3390/ijms25073746

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop